Bradley J. Demuth

Bradley J. Demuth’s practice is focused on complex antitrust litigation with particular expertise in cases involving pharmaceutical overcharges resulting from delayed generic entry schemes, price fixing, and other anticompetitive conduct.  Brad is a partner in the firm’s New York office.

Upon graduating, cum laude, from American University Washington College of Law, Brad served as a law clerk to the United States Court of Appeals for the Second Circuit.  Thereafter, Brad associated with Cadwalader, Wickersham & Taft LLP and Skadden, Arps, Slate, Meager & Flom LLP, where he successfully represented several national and multinational corporate defendants in a wide range of antitrust disputes.  His antitrust experience includes litigating issues in the pharmaceutical, high-tech, professional sports, consumer goods, luxury goods, financial benchmarking, commodities, and industrial materials contexts.

As a partner of the firm, Brad has made notable contributions in several high-profile pharmaceutical antitrust cases that resulted in significant recoveries, including in:

• In re Zetia (Ezetimibe) Antitrust Litigation (E.D. Va.)
• Value Drug Co. v. Takeda Pharmaceuticals U.S.A., Inc. (E.D. Pa.) (re Colcrys)
• In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation (E.D.N.Y.)

Brad is currently involved in several other pending high-profile pharmaceutical antitrust matters including In re Generic Pharmaceutical Pricing Antitrust Litigation (E.D. Pa.) and In re Bystolic Antitrust Litigation (S.D.N.Y.).

Brad is a member of the New York State bar and is admitted to practice before the United States Court of Appeals for the Second Circuit, and the United States District Courts for the Southern and Eastern Districts of New York and the District of Colorado.